H.C. Wainwright analyst Edward White lowered the firm’s price target on InflaRx to $9 from $10 and keeps a Buy rating on the shares. The target change reflects an increased number of shares after the company announced the full exercise of the underwriters’ option to purchase an added 1.41M shares of common stock in connection with the company’s previously announced public offering of 9.41M shares at a price of $4.25. The firm estimates Gohibic sales of $199M in 2028, which includes $91M in the COVID-19 indication and $108M in PG, and notes that it does not assign any value to other development-stage programs.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IFRX:
- InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
- InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
- InflaRx 9.41M share Spot Secondary priced at $4.25
- InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
- InflaRx TBA Spot Secondary; price range $4.00-$4.25
